To main content To main navigation

KWF grant to research TIL therapy as a treatment for advanced uterine cancer
News
Published
KWF has provided a €4.1 million grant for the development of TIL-therapy for patients with advanced uterine cancer. In this study, Hilde Jalving and Liesbeth de Vries (medical oncology), Marjolijn Lub-de Hooge (clinical pharmacy and pharmacology) and Adrienne Brouwers (nuclear medicine & molecular imaging) are collaborating with colleagues from the AvL/NKI. Project leader is Tom Seijkens from the Netherlands Cancer Institute.
TIL therapy

The TIL-TEC study aims to develop a new treatment for patients with advanced uterine cancer. TILs are tumour-infiltrating lymphocytes (white blood cells) and are isolated from a piece of tumour tissue from the patient. These ‘good’ immune cells are grown outside the body and then given back to the patient after pretreatment with chemotherapy. This treatment is given once.

During the study molecular imaging techniques (CD8-PET scans) will be performed to see if they can be used in the future to select the best piece of tumour for TIL harvest. Furthermore, these imaging techniques provide insight into the distribution of TIL cells in the patient. This knowledge can then be used to improve and refine the therapy.

The study is conducted in close collaboration between the AvL/NKI and the UMCG.